top of page
  • ODI Pharma

Final registration of ODI Pharma’s new share issue completed

Stockholm, 20.01.2020. As communicated earlier today, ODI Pharma AB's (“ODI Pharma” or “Company”) recently completed new share issue has been partially registered at the Swedish Companies Registration Office. The Company now announces that the second and final part of the Company's new share issue has been registered. In the second registration, 140,886 shares were registered, which means that ODI Pharma's total number of shares now amounts to 15,220,000 and the share capital amounts to SEK 608,800.00.

Listing on Spotlight Stock Market

The first day of trading in ODI Pharma’s shares on Spotlight Stock Market will be the 23rd of January 2020. The short name for the share is “ODI” and the ISIN-code is SE0013409760.

Financial and legal advisor

Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor in the new share issue and the listing on Spotlight Stock Market.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB


For more information regarding the new share issue and listing, please contact:

Sedermera Fondkommission

Phone: +46 40 615 14 10


ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB: Updated market and business overview

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe. Progress in the cooper

ODI Pharma AB: Publication of half-year report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2023. The report is available as an attached document to this press release and on the Compa


Original on Transparent.png
bottom of page